The Multiple Myeloma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in multiple myeloma. Our aim is to enhance knowledge in multiple myeloma, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
IMS 2026 | CARTITUDE-2 Cohort A: ≥5-year remission and survival with cilta-cel in RRMM
During the 23rd International Myeloma Society (IMS) Annual Meeting and Exposition, September 23–26, 2026, Glasgow, UK, the Multiple Myeloma Hub spoke with María-Victoria Mateos, University Hospital of Salamanca, ES. We asked about the long-term outcomes with ciltacabtagene autoleucel (cilta-cel) in patients with relapsed/refractory multiple myeloma (RRMM) in Cohort A of the CARTITUDE-2 trial.
In this interview, Mateos discusses the ≥5-year findings from Cohort A of the phase II CARTITUDE-2 trial (NCT04133636), which evaluated a single cilta-cel infusion in patients with RRMM after 1–3 prior lines of therapy who were exposed to a proteasome inhibitor and are lenalidomide-refractory. Mateos reviews long-term remission and survival outcomes, characteristics associated with prolonged disease control, immune correlates of durable response, and long-term safety findings. Mateos also discusses these findings in the context of cilta-cel use in earlier lines of therapy.
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
6 Oct 2026
IMS 2026 | UKMRA ProMMise D interim results: VRAT-guided belantamab mafodotin dosing in RRMM
During the 23rd International Myeloma Society (IMS) Annual Meeting and Exposition, September 23–26, 2026, Glasgow, UK, the Multiple Myeloma Hub spoke with Rakesh Popat, University College Hospital, London, UK. We asked about interim results from Arm D of the UKMRA ProMMise trial in patients with relapsed/refractory multiple myeloma (RRMM).
In this interview, Popat discusses interim results from Arm D of the ProMMise trial, which is evaluating a vision-related anamnestic tool (VRAT) to assess ocular symptoms and function, and guide belantamab mafodotin dosing in patients with RRMM receiving belantamab mafodotin + bortezomib + dexamethasone (BVd). Popat reviews interim results from Stage 1, including the correlation between VRAT and ocular assessments, and outlines the planned evaluation of VRAT-guided dosing without mandated ocular examinations in Stage 2.
Intended for healthcare professionals. This educational resource is independently supported by GSK. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
29 Sept 2026
How to optimize outpatient delivery of bispecific antibody therapy for MM
The Multiple Myeloma Hub spoke with Rakesh Popat, UCL Hospitals NHS Foundation Trust, London, UK. We asked how to optimize outpatient delivery of bispecific antibody therapy for multiple myeloma (MM).
In this interview, Popat discusses practical strategies to support the outpatient delivery of bispecific antibody therapy, including patient selection, caregiver support, and access to timely medical care if needed. Popat also outlines approaches that could facilitate step-up dosing in the outpatient setting, such as strategies to reduce the risk of cytokine release syndrome (CRS) and the potential use of wearable technology and remote monitoring.
Intended for healthcare professionals. This educational resource is independently supported by Johnson & Johnson. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
Who has been a guest on Multiple Myeloma Hub
Names identified in recent episode analyses. Showing up to five guests.
Shaji Kumar
Hang Quach
Paul Richardson
María-Victoria Mateos
Morie Gertz
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
YouTube views
597,144
Score snapshot 15 Sept 2025
Apple Podcasts (US)
3.4 / 5
5 ratings
Podcast Authority Score: 36 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
25
Social presence
0
YouTube
86
Engagement
31
Contact Multiple Myeloma Hub
Guest appearances
Does not typically book guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
